|
|
|
|
|||||
|
|
|
Insmed Incorporated (NASDAQ:INSM) is one of the best stocks to invest in right now. On September 19, RBC Capital analyst Leonid Timashev maintained a Buy rating on Insmed Incorporated (NASDAQ:INSM) and set a price target of $138.00.
Insmed Incorporated (NASDAQ:INSM) reported in its fiscal Q2 2025 results that total revenue for ARIKAYCE reached $107.4 million for the quarter, reflecting a growth of 19% over fiscal Q2 2024.
Insmed Incorporated (NASDAQ:INSM) is a global biopharmaceutical company that develops and commercializes therapies for patients with rare diseases. The company focuses on the Brensocatib and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline.
While we acknowledge the potential of INSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
| 7 hours | |
| Sep-30 | |
| Sep-27 | |
| Sep-22 | |
| Sep-12 | |
| Sep-05 | |
| Sep-05 | |
| Sep-04 |
Insmed scores pivotal win in bronchiectasis with FDA approval of Brinsupri
INSM
Pharmaceutical Technology
|
| Sep-03 | |
| Sep-02 |
Why United Therapeutics Catapulted 33%, Pulling Insmed, Liquidia With It
INSM
Investor's Business Daily
|
| Sep-02 |
Why United Therapeutics Just Catapulted 35%, Pulling Insmed, Liquidia With It
INSM
Investor's Business Daily
|
| Sep-02 | |
| Aug-27 | |
| Aug-22 | |
| Aug-21 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite